Skip to main content
Premium Trial:

Request an Annual Quote

Decode Genetics Gets Stay from Nasdaq Delisting

NEW YORK (GenomeWeb News) – Decode Genetics said last night that it has received a letter from the Nasdaq that effectively stays delisting of the firm's stock from the Nasdaq Capital Market, which could have occurred tomorrow.

The Nasdaq Listing and Hearing Review Council called for a review of an April 22 determination of the Nasdaq Listing Qualifications Panel that it would have delisted Decode's shares on April 30.

The firm's shares will continue to trade on the Nasdaq Capital Market during the review period. Decode did not provide an estimate of how long the review would take.

Decode's shares have been under threat of delisting for several months. The cash-strapped firm said in December that it was conducting a review of its business strategy with a goal of sharpening its business focus and selling non-core assets, among other aims.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.